| Study of Bevacizumab in Combination with Alternating XELIRI and XELOX in Metastatic Colorectal Cancer (NCT01531595) | Pia Osterlund | 2012-02-01 |
| QUILT-3.019: Phase 2 Study of NPC-1C Chimeric Monoclonal Antibody to Treat Pancreatic and Colorectal Cancer (NCT01040000) | Precision Biologics, Inc | 2012-01-01 |
| Potential Predictive Biomarkers in Patients Undergoing First-line Chemotherapy for Metastatic Colorectal Cancer (NCT03532711) | Fudan University | 2012-01-01 |
| A Non-Interventional Follow-Up to the VELOUR Study - Translational Research (NCT01754272) | KU Leuven | 2012-01-01 |
| Trial of FOLF(HA)Iri Versus FOLFIRI in mCRC (NCT01290783) | Alchemia Oncology | 2011-12-01 |
| A Retrospective Review of Liver Resection Rate in Metastatic Colorectal Cancer Patients Following Downsizing Treatment With Chemotherapy Plus Cetuximab in Normal UK National Health Service Clinical Practice (NCT01460745) | Merck KGaA, Darmstadt, Germany | 2011-11-01 |
| A Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and mFOLFOX-6 in Participants With Previously Untreated Metastatic Colorectal Cancer (NCT01399684) | Genentech, Inc. | 2011-11-01 |
| Comparison of Survival Benefit of Panitumumab With Supportive Care to Best Supportive Care Alone in Patients With Metastatic Colorectal Cancer (NCT01412957) | Amgen | 2011-11-01 |
| A Phase II Study of Gemcitabine and Capecitabine for Treatment Resistant, Metastatic Colorectal Cancer (NCT01472770) | Vejle Hospital | 2011-10-01 |
| Induction Chemoterapy With Folfoxiri Plus Cetuxumab in Unresectable Colorectal Cancer Patient (NCT02295930) | Gruppo Oncologico del Nord-Ovest | 2011-10-01 |
| 2nd-line Treatment of Metastatic Colorectal Cancer (NCT01532804) | Institut du Cancer de Montpellier - Val d'Aurelle | 2011-07-28 |
| Efficacy of FOLFOX+Bevacizumab in Combination With Irinotecan in the Treatment of Metastatic Colorectal Cancer (NCT01321957) | Martin-Luther-Universität Halle-Wittenberg | 2011-05-01 |
| Study of IMMU-130 in Patients With Relapsed/Refractory Colorectal Cancer (NCT01270698) | Gilead Sciences | 2011-05-01 |
| Recombinant Anti-tumor and Anti-virus Protein for Injection in Treatment of Metastatic Colorectal Cancer (NCT01386242) | The Affiliated Hospital of the Chinese Academy of Military Medical Sciences | 2011-05-01 |
| PERfusion CT in the FOXFIRE Trial to Study Blood Flow to Liver Metastases (NCT01410760) | University of Oxford | 2011-04-01 |
| Efficacy and Safety of the Prophylactic Use of Doxycycline +/- Vitamin K Cream (NCT01345526) | Universitätsmedizin Mannheim | 2011-04-01 |
| Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type RAS Who Have Resected Hepatic Metastases From Colorectal Cancer (NCT01312857) | Memorial Sloan Kettering Cancer Center | 2011-03-07 |
| IXO+A in mCRC With Liver-only Metastases (NCT01293942) | Ottawa Hospital Research Institute | 2011-03-01 |
| Study of TF2 Carcinoembryonic Antigen (CEA) Antibody in Patients With Metastatic Colorectal Cancer (NCT01273402) | Gilead Sciences | 2011-02-01 |
| Efficacy And Safety Of Xeliri + Avastin Followed By Xelox + Avastin Or Reverse Sequence In Metastatic Colorectal Cancer (NCT02119026) | Prof. Dr. Werner Scheithauer | 2011-02-01 |
| Circulating Tumor Cells and Neutrophils Count for Colorectal Metastatic Cancer (NCT05793775) | Centre Hospitalier Universitaire de Nice | 2011-02-01 |
| Study Assessing Potential Predictive Tumor Markers in Metastatic Colorectal Cancer (NCT01288339) | Grupo Espanol Multidisciplinario del Cancer Digestivo | 2010-11-08 |
| Dual Targeting of Vascular Endothelial Growth Factor-A Together With Angiopoietins in Chemotherapy-naïve Metastatic Colorectal Cancer (NCT01249521) | Austin Health | 2010-11-01 |
| Simvastatin + Cetuximab/Irinotecan in K-ras Mutant Colorectal Cancer (CRC) (NCT01281761) | Samsung Medical Center | 2010-11-01 |
| A Trial to Compare Oxaliplatin, Folinic Acid (FA) and 5-Fluorouracil (5FU) Combination Chemotherapy (FOLFOX-4) With or Without Cetuximab in the 1st Line Treatment of Metastatic Colorectal Cancer (mCRC) in Chinese Rat Sarcoma Viral Oncogene Homolog (RAS) Wild-type Patients (NCT01228734) | Merck KGaA, Darmstadt, Germany | 2010-09-09 |
| FOLFOX/Bevacizumab +/- MK-0646 in Metastatic Colorectal Cancer (NCT01175291) | H. Lee Moffitt Cancer Center and Research Institute | 2010-09-01 |
| Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer (NCT01174121) | National Cancer Institute (NCI) | 2010-08-26 |
| Study of NK012 and 5-FU/LV in Solid Tumors Followed by Dose Expansion in Colorectal Cancer (NCT01238939) | Nippon Kayaku Co., Ltd. | 2010-08-01 |
| Safety and Efficacy Study of mFOLFOX-6 Plus Cetuximab for 8 Cycles Followed by mFOLFOX-6 Plus Cetuximab or Single Agent Cetuximab as Maintenance Therapy in Patients With Metastatic Colorectal Cancer and WT KRAS Tumours (NCT01161316) | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | 2010-08-01 |
| Everolimus and OSI-906 for Patients With Refractory Metastatic Colorectal Cancer (NCT01154335) | SCRI Development Innovations, LLC | 2010-07-01 |
| Xeloda Maintenance Versus BSC in Metastatic Colorectal Cancer (NCT02060669) | Samsung Medical Center | 2010-06-20 |
| Study of CS-1008 in Combination With FOLFIRI in Patients Who Have Failed Other Treatments (NCT01124630) | Daiichi Sankyo | 2010-05-01 |
| Impact of Early and Active Nutritional and Dietary Management grade3 or More Toxicities Induced by Chemotherapy and Targeted Therapies Administered to Patients as First Intention for Non Surgical Metastatic Colorectal Cancer (NCT01143285) | Centre Hospitalier Universitaire de Nice | 2010-04-01 |
| Pemetrexed and Gemcitabine for Treatment Resistant Patients With Metastatic Colorectal Cancer and KRAS Mutations (NCT01109615) | Vejle Hospital | 2010-04-01 |
| Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy (NCT01103323) | Bayer | 2010-04-01 |
| Combination Chemotherapy and Cetuximab or Bevacizumab in Treating Patients With Metastatic Colorectal Cancer (NCT01280643) | Fox Chase Cancer Center | 2010-03-01 |
| MEK Inhibitor MSC1936369B Plus FOLFIRI in Second Line K-Ras Mutated Metastatic Colorectal Cancer (mCRC) (NCT01085331) | EMD Serono | 2010-03-01 |
| ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer (NCT01001377) | Amgen | 2010-02-02 |
| ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer (NCT01075048) | Daiichi Sankyo | 2010-01-26 |
| Chemotherapy for Resectable Colorectal Liver Metastases (NCT04513457) | Fundación de Investigación Biomédica - Hospital Universitario de La Princesa | 2010-01-01 |
| A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver (NCT00803647) | NSABP Foundation Inc | 2010-01-01 |
| Irinotecan, Cetuximab and Everolimus to Patients With Metastatic Colorectal Cancer (NCT01387880) | Herlev Hospital | 2010-01-01 |
| A Genotype-guided Study of Irinotecan Administered in Combination With 5-fluorouracil/Leucovorin (FOLFIRI) and Bevacizumab in Advanced Colorectal Cancer Patients (NCT01183494) | University of Chicago | 2009-12-12 |
| PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study (NCT00911170) | Amgen | 2009-11-03 |
| Efficacy/Safety Study of Bevacizumab,Capecitabine,Oxaliplatin to Metastatic Colorectal Adenocarcinoma Elderly Patients. (NCT01067053) | Grupo Espanol Multidisciplinario del Cancer Digestivo | 2009-11-01 |
| Dose Adaptation of Capecitabine Using Mobile Phone Toxicity Monitoring (NCT01053104) | University of Oxford | 2009-11-01 |
| An Observational Study of CPT-11 Based Regimens and UGT1A1 Genotypes in Metastatic Colorectal Cancer (mCRC) (NCT01039506) | Daiichi Sankyo Co., Ltd. | 2009-10-15 |
| EMD 525797 in Combination With Cetuximab and Irinotecan in K-ras Wild Type Metastatic Colorectal Cancer (NCT01008475) | Merck KGaA, Darmstadt, Germany | 2009-10-01 |
| Biomarker - Panitumumab Response With KRAS Wild Type MCC (NCT00853931) | British Columbia Cancer Agency | 2009-10-01 |
| A Study to Assess PV-10 Chemoablation of Cancer of the Liver (NCT00986661) | Provectus Biopharmaceuticals, Inc. | 2009-10-01 |
| A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study (NCT00959647) | Genentech, Inc. | 2009-09-03 |
| A Clinical Trial of Panitumumab in Combination With FOLFIRI Chemotherapy as Second Line Treatment in Subjects With Metastatic Colorectal Cancer Expressing Wild-type KRAS and Who Had Progressed ≥ 6 Months After the Last Dose of the First Line Chemotherapy (NCT01144195) | Associacio catalana per a la recerca oncologica i les seves implicacions sanitaries i socials | 2009-09-01 |
| Trial Comparing Two Two Sequences of Therapy in Colorectal Metastatic Patients (NCT01030042) | Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente | 2009-09-01 |
| A Study of ARRY-438162 (MEK162) in Patients With Advanced Cancer (NCT00959127) | Array Biopharma, now a wholly owned subsidiary of Pfizer | 2009-08-01 |
| Study of Capecitabine and Cetuximab as First-Line Therapy in Patients With Metastatic Wild Type Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Colorectal Cancer (NCT00954876) | Translational Genomics Research Institute | 2009-08-01 |
| Sunitinib and Capecitabine for First Line Colon Cancer (NCT00961571) | Georgetown University | 2009-08-01 |
| Safety and Efficacy Study of Panitumumab+Irinotecan in Patients Wild-Type (WT) KRAS Metastatic Colorectal Cancer Refractory to Irinotecan Based Chemotherapy (SPECTRA) (NCT00958386) | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | 2009-08-01 |
| CS-1008 Used With Irinotecan Versus Irinotecan Alone in Subjects With Metastatic Colorectal Carcinoma Who Failed First-line Treatment With Oxaliplatin (NCT00969033) | Daiichi Sankyo | 2009-07-01 |
| CY-503 for the Treatment of Chemotherapy-refractory Metastatic Colorectal Cancer (NCT00932724) | Cytavis Biopharma GmbH | 2009-07-01 |
| Assessment of Clinical Practice Administration of Chemotherapy and Anti-angiogenic Agent (Bevacizumab) in Colorectal Cancer (NCT01811108) | Hellenic Oncology Research Group | 2009-07-01 |
| Phase I and Pharmacokinetic Study of Biweekly PEP02 in mCRC Refractory to 1st-line Oxaliplatin Base Therapy (NCT00940758) | PharmaEngine | 2009-06-01 |
| A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (NCT00931840) | Enzon Pharmaceuticals, Inc. | 2009-06-01 |
| First-line FOLFOXIRI Plus Bevacizumab in BRAF Mutant Metastatic Colorectal Cancer (NCT01437618) | Azienda Ospedaliero, Universitaria Pisana | 2009-06-01 |
| Study of CMAB009 to Treat KRAS Wild Type Metastatic Colorectal Cancer (NCT01550055) | Shanghai Zhangjiang Biotechnology Limited Company | 2009-05-31 |
| Study to Evaluate Mechanisms of Acquired Resistance to Panitumumab (NCT00891930) | NantBioScience, Inc. | 2009-05-05 |
| XAD - Xelox (Capecitabine + Oxaliplatin) + Bevacizumab + Dasatinib (NCT00920868) | Herbert Hurwitz, MD | 2009-05-01 |
| A Study of Dulanermin Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, or Metastatic Colorectal Cancer (NCT00873756) | Genentech, Inc. | 2009-05-01 |
| Study to Evaluate the Safety, Tolerability and Efficacy of FOLFOX + CT-011 Versus FOLFOX Alone (NCT00890305) | Medivation, Inc. | 2009-05-01 |
| A Study of PRO95780 Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, and Metastatic Colorectal Cancer (APM4566g) (NCT00851136) | Genentech, Inc. | 2009-05-01 |
| PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors (NCT00819780) | Amgen | 2009-04-24 |
| Irinotecan, Capecitabine and Bevacizumab in Metastatic Colorectal Cancer Patients (NCT00875771) | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | 2009-04-01 |
| Erbitux Study of CPT11, Oxaliplatin, UFToral Targeted Therapy (NCT01225744) | The Christie NHS Foundation Trust | 2009-04-01 |
| Evaluation of VEGF Polymorphism as Predictive Factor in Metastatic Colorectal Cancer Treated With Folfiri Plus Bevacizumab (NCT01363739) | Azienda Ospedaliero, Universitaria Pisana | 2009-04-01 |
| Temsirolimus and Irinotecan for Treatment Resistant Patients With Metastatic Colorectal Cancer and KRAS Mutations (NCT00827684) | Vejle Hospital | 2009-03-01 |
| Sorafenib With Irinotecan in Metastatic Colorectal Cancer (mCRC) and K-RAS Mutation (NCT00989469) | Institut du Cancer de Montpellier - Val d'Aurelle | 2009-02-01 |
| Study of Chemoembolisation Using Irinotecan Bead Prior to Surgery in Metastatic Colorectal Cancer (NCT00844233) | Boston Scientific Corporation | 2009-02-01 |
| Bi-weekly Cetuximab Combined With 5-fluorouracil/Leucovorin/Oxaliplatin (FOLFOX-6) in Metastatic Colorectal Cancer (NCT01051167) | Martin Schuler, Prof. Dr. med. | 2009-02-01 |
| Study Evaluating the Safety and Efficacy of FOLFIRI Plus Cetuximab or FOLFOX Plus Cetuximab as First-line Therapy in Subjects With KRAS Wild-type Metastatic Colorectal Cancer (APEC-Study) (NCT00778830) | Merck KGaA, Darmstadt, Germany | 2009-02-01 |
| Post-First Progression Use of Bevacizumab in Metastatic Colorectal Cancer (mCRC) (NCT00862342) | Asan Medical Center | 2009-01-01 |
| A Trial of Capecitabine (Xeloda), Oxaliplatin and Irinotecan in Combination With Bevacizumab in 1st Line Treatment of Metastatic Colorectal Cancer (NCT01311050) | King Faisal Specialist Hospital & Research Center | 2009-01-01 |
| Positron Emission Tomography - Computed Tomography (PET-CT) Cetuximab Project (NCT00828620) | Universitaire Ziekenhuizen KU Leuven | 2009-01-01 |
| Irinotecan and Panitumumab as 3rd Line Treatment for mCRC Without KRAS Mutations (NCT00792363) | Vejle Hospital | 2008-11-01 |
| A Phase 2, Randomized, Double Blind, Placebo Controlled Study of AMG 386 in Combination With FOLFIRI in Subjects With Previously Treated Metastatic Colorectal Carcinoma (NCT00752570) | Amgen | 2008-11-01 |
| Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC) (NCT00788957) | NantBioScience, Inc. | 2008-10-27 |
| A Phase I Trial Evaluating mFOLFOX6 and Avastin With Nexavar as First-Line Treatment for Metastatic Colorectal Cancer (NCT00779311) | Accelerated Community Oncology Research Network | 2008-10-01 |
| Dual Inhibition of EGFR Signalling Using the Combination of Cetuximab and Erlotinib (NCT00784667) | Austin Health | 2008-10-01 |
| Phase I Trial of Sorafenib + FOLFIRI In Metastatic Colorectal Cancer (NCT00780169) | Ottawa Hospital Research Institute | 2008-10-01 |
| FOLFIRI and Sunitinib in Metastatic Colorectal Cancer (NCT00806663) | Central European Society for Anticancer Drug Research | 2008-08-01 |
| Optimal Control of Liver Metastases From Colorectal Cancer With Cetuximab and Hepatic Artery Infusion of Chemotherapy (NCT00852228) | Association pour la Recherche sur le Temps Biologique et la Chronothérapie | 2008-07-01 |
| A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) With Concurrent Chemotherapy and Bevacizumab As First-Line Therapy for Metastatic Colorectal Cancer (NCT00636610) | Genentech, Inc. | 2008-05-01 |
| Observation of Patients With Metastatic Colorectal Cancer Starting Chemotherapy Combined With Bevacizumab (Avastin) (NCT02612077) | Hoffmann-La Roche | 2008-05-01 |
| Irinotecan, Capecitabine and Avastin for Metastatic Colorectal Cancer as Salvage Treatment (NCT00717990) | University Hospital of Crete | 2008-04-01 |
| FLOX + Cetuximab (Erbitux®) for Patients With Metastatic Colorectal Cancer and Wild Type K-RAS Tumor (NCT00660582) | Per Pfeiffer | 2008-04-01 |
| Effect of Panitumumab on the Pharmacokinetics of Irinotecan (NCT00563316) | Amgen | 2008-03-01 |
| Erlotinib and Chemotherapy for 2nd Line Treatment (Tx) of Metastatic Colorectal Cancer (mCRC) (NCT00642746) | OHSU Knight Cancer Institute | 2008-03-01 |
| Alpha-type-1 Dendritic Cell-based Vaccines in Patients With Metastatic Colorectal Cancer (NCT00558051) | Pawel Kalinski | 2008-01-01 |
| Conatumumab/Panitumumab Combination Metastatic Colorectal Cancer Study (NCT00630786) | Amgen | 2008-01-01 |
| A Post-Marketing Surveillance Study On Erbitux® (Cetuximab) In Patients With Metastatic Colorectal Cancer Refractory To Irinotecan Containing Treatment (NCT01134640) | Merck KGaA, Darmstadt, Germany | 2008-01-01 |
| Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Metastatic Colorectal Cancer (MK-0646-004) (NCT00614393) | Merck Sharp & Dohme LLC | 2007-12-24 |
| Sequential Treatment Strategy for Metastatic Colorectal Cancer (NCT01878422) | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | 2007-11-01 |